Corium International Inc (NASDAQ:CORI) – Investment analysts at Cantor Fitzgerald increased their FY2018 earnings estimates for shares of Corium International in a research report issued to clients and investors on Monday. Cantor Fitzgerald analyst W. Tanner now expects that the biopharmaceutical company will post earnings of ($1.19) per share for the year, up from their previous estimate of ($1.33). Cantor Fitzgerald currently has a “Buy” rating and a $14.00 target price on the stock. Cantor Fitzgerald also issued estimates for Corium International’s FY2019 earnings at ($0.84) EPS.
Corium International (NASDAQ:CORI) last released its earnings results on Thursday, February 8th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.43) by $0.06. Corium International had a negative net margin of 148.07% and a negative return on equity of 331.37%. The firm had revenue of $9.32 million for the quarter, compared to analyst estimates of $7.48 million.
Corium International (NASDAQ CORI) traded up $0.45 during mid-day trading on Wednesday, hitting $12.48. 189,800 shares of the company were exchanged, compared to its average volume of 193,629. The company has a debt-to-equity ratio of 2.41, a quick ratio of 2.60 and a current ratio of 2.70. Corium International has a 12-month low of $2.95 and a 12-month high of $13.93.
In related news, major shareholder Perceptive Advisors Llc purchased 50,350 shares of the company’s stock in a transaction on Tuesday, January 16th. The shares were bought at an average cost of $11.83 per share, for a total transaction of $595,640.50. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Healthcare Master Fun Broadfin sold 500,000 shares of the stock in a transaction that occurred on Friday, November 17th. The shares were sold at an average price of $10.96, for a total transaction of $5,480,000.00. The disclosure for this sale can be found here. Corporate insiders own 30.80% of the company’s stock.
A number of institutional investors have recently made changes to their positions in the business. Renaissance Technologies LLC increased its stake in Corium International by 14.0% in the fourth quarter. Renaissance Technologies LLC now owns 96,900 shares of the biopharmaceutical company’s stock valued at $931,000 after purchasing an additional 11,900 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Corium International by 6.0% in the fourth quarter. Geode Capital Management LLC now owns 223,536 shares of the biopharmaceutical company’s stock valued at $2,147,000 after acquiring an additional 12,745 shares during the period. Schwab Charles Investment Management Inc. boosted its holdings in shares of Corium International by 47.3% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 49,509 shares of the biopharmaceutical company’s stock valued at $476,000 after acquiring an additional 15,909 shares during the period. New York State Common Retirement Fund acquired a new stake in shares of Corium International in the second quarter valued at approximately $158,000. Finally, Bank of New York Mellon Corp boosted its holdings in shares of Corium International by 33.7% in the third quarter. Bank of New York Mellon Corp now owns 88,445 shares of the biopharmaceutical company’s stock valued at $980,000 after acquiring an additional 22,285 shares during the period. Institutional investors own 89.04% of the company’s stock.
TRADEMARK VIOLATION WARNING: “FY2018 EPS Estimates for Corium International Inc Raised by Cantor Fitzgerald (CORI)” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://www.americanbankingnews.com/2018/02/14/fy2018-eps-estimates-for-corium-international-inc-raised-by-cantor-fitzgerald-cori.html.
About Corium International
Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.
Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.